The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Eder, Ann-Christin; Omrane, Mohamed Aymen; Stadlbauer, Sven; Roscher, Mareike; Khoder, Wael; Gratzke, Christian; Kopka, Klaus; Eder, Matthias; Meyer, Philipp T.; Jilg, Cordula A.; Ruf, Juri

doi:10.1007/s00259-020-05184-0

Cited by 25 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of particular interest for robotic surgery are methods providing images, which can be played back in the surgeon's console and thus, for example, letting him or her see which margins to extend. Intraoperative imaging modalities like portable gamma camera scintigraphy and single-band fluorescence imaging have been shown to provide valuable information not only in radio-guided occult lesion localization setups, for instance [206,207], but also in more challenging applications like PSMA-guided surgery [29]. An interesting approach that has made it through the regulatory path into the market is Cerenkov luminesce.…”

Section: Molecular Imaging Methodsmentioning

confidence: 99%

“…Following the success in SLNB, this hybrid concept is now increasingly adopted for research in receptor-targeted tracers (e.g., neuroendocrine tumors using Cy5- 111 In-DTPA-Tyr3-octreotate [156], prostate cancer using PSMA I&F [157] and breast cancer using 111 In-DTPA-trastuzumab IRDye800 (Wang2015)). There, some have recently even entered first-in-human studies (e.g., clear cell renal cell carcinoma using 111 In-DOTA-girentuximab IRDye800 [30] or prostate cancer using 64 Ga-PSMA-914 [29]).…”

Section: Single-band Fluorescence Imagingmentioning

confidence: 99%

See 1 more Smart Citation

How molecular imaging will enable robotic precision surgery

Wendler

Leeuwen

Navab

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Molecular imaging is one of the pillars of precision surgery. Its applications range from early diagnostics to therapy planning, execution, and the accurate assessment of outcomes. In particular, molecular imaging solutions are in high demand in minimally invasive surgical strategies, such as the substantially increasing field of robotic surgery. This review aims at connecting the molecular imaging and nuclear medicine community to the rapidly expanding armory of surgical medical devices. Such devices entail technologies ranging from artificial intelligence and computer-aided visualization technologies (software) to innovative molecular imaging modalities and surgical navigation (hardware). We discuss technologies based on their role at different steps of the surgical workflow, i.e., from surgical decision and planning, over to target localization and excision guidance, all the way to (back table) surgical verification. This provides a glimpse of how innovations from the technology fields can realize an exciting future for the molecular imaging and surgery communities.

show abstract

Section: Molecular Imaging Methodsmentioning

confidence: 99%

Section: Single-band Fluorescence Imagingmentioning

confidence: 99%

How molecular imaging will enable robotic precision surgery

Wendler

Leeuwen

Navab

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…In urology or surgery, PSMA PET and intraoperative fluorescence using the same molecule might help to identify malignant tissue. Recently, a novel hybrid tracer based on PSMA-11 has been reported for fluorescence-guided surgery in prostate cancer [ 55 ], and future work is expected to considerably improve lymphadenectomy. PSMA-11 imaging might also have a significant role in primary diagnosis, as demonstrated in a more recent study by Fendler et al [ 17 ].…”

Section: Perspectivementioning

confidence: 99%

[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

Hennrich

Eder

2021

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [68Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first 68Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide 68Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.

show abstract

“…More recently, the linker design of Glu-urea-Lys-HBED-CC-IRDye800CW was modified by insertion of histidine- and glutamic acid spacers ((HE) 3 ) near the PSMA binding motif to further reduce background uptake in non-target tissue and to accelerate excretion [ 138 , 139 ]. Glu-urea-Lys-(HE) 3 -HBED-CC-IRDye800CW (PSMA-914) was used in a proof-of-concept study, with a first, pre-operative PET/CT imaging, 1-day prior surgery in a patient with high-risk prostate carcinoma and a second PET/CT imaging, after the surgical removal of the primary tumor [ 140 ]. 68 Ga-radiolabeled PSMA-914 and PSMA-914 alone were administered 1-h prior to PET imaging and DaVinci robot-assisted prostatectomy respectively.…”

Section: Psma Inhibitors For Guided Surgerymentioning

confidence: 99%

Radiolabeled PSMA Inhibitors

Neels

Kopka

Liolios

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

PSMA has shown to be a promising target for diagnosis and therapy (theranostics) of prostate cancer. We have reviewed developments in the field of radio- and fluorescence-guided surgery and targeted photodynamic therapy as well as multitargeting PSMA inhibitors also addressing albumin, GRPr and integrin αvβ3. An overview of the regulatory status of PSMA-targeting radiopharmaceuticals in the USA and Europe is also provided. Technical and quality aspects of PSMA-targeting radiopharmaceuticals are described and new emerging radiolabeling strategies are discussed. Furthermore, insights are given into the production, application and potential of alternatives beyond the commonly used radionuclides for radiolabeling PSMA inhibitors. An additional refinement of radiopharmaceuticals is required in order to further improve dose-limiting factors, such as nephrotoxicity and salivary gland uptake during endoradiotherapy. The improvement of patient treatment achieved by the advantageous combination of radionuclide therapy with alternative therapies is also a special focus of this review.

show abstract

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Cited by 25 publications

References 6 publications

How molecular imaging will enable robotic precision surgery

How molecular imaging will enable robotic precision surgery

[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

Radiolabeled PSMA Inhibitors

Contact Info

Product

Resources

About